(PQB5) Does the timing of Pten and Rb1 mutation affect prostate cancer phenotypes
(PQB5) Pten 和 Rb1 突变的时间是否影响前列腺癌表型
基本信息
- 批准号:8587206
- 负责人:
- 金额:$ 22.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-01 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAllelesAndrogensBehaviorBindingBreedingCancer ModelCancer PatientCancer PrognosisCellsChimeric ProteinsDataDiseaseEnsureEpigenetic ProcessEstrogen ReceptorsFutureGene MutationGenesGeneticGenetic EngineeringGenetic Predisposition to DiseaseGenetic RecombinationGenetic TranscriptionGenetically Engineered MouseGoalsHistologicHumanMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of prostateMediatingMethodologyMusMutationNaturePTEN genePatternPerformancePhenotypeProcessRB1 geneRecurrenceRetinoblastomaSiteStagingSystemTamoxifenTestingTimeTissuesTransgenesTransgenic MiceTranslationsVariantbasecancer cellcancer initiationcancer therapydeprivationdesignexpectationhuman diseasein vivointerestlung small cell carcinomamouse modelnovelprostate cancer modelpublic health relevancerecombinaseresponsetumor progression
项目摘要
DESCRIPTION (provided by applicant): Cancer progression is driven by an evolutionary process of genetic mutation, phenotypic variation, and selection. The genetic background of cancer cells is thus continuously changing. Genetic background will dictate the nature of future mutations that can be tolerated and selected for. The effects of specific new mutations will depend on the genetic background in which they occur. Thus the temporal order of mutations is expected to influence cancer phenotype. How the timing of mutation affects cancer phenotypes remains a largely unanswered question, however. Answering this provocative question (PQB5) is significant because cancer prognosis and effective personalized cancer treatment will depend not only on the nature of mutations present within a particular cancer, but also on the order in which they are acquired. Genetically engineered mouse cancer models have been vital in elucidating the genetic etiology of cancer, but have rarely been used to address PQB5. This is due to limitations inherent in commonly used genetic engineering methodology; when multiple mutations are created, the order of mutations is either unknown, is not controllable, or is not restricted to incipient cancer cells. A current barrier to progress is the availability of mouse cancer models that allow precise control over the timing and order of multiple genetic mutations. We propose to overcome this barrier by developing a novel mouse cancer model based on a lox-neo/stop-lox FlpO-ERT2 transgene. This transgene encodes an FlpO recombinase, ERT2 estrogen receptor fusion protein whose activity is tamoxifen inducible. The transgene is combined with tissue specific Cre transgenes, floxed alleles of the cancer initiating mutation, and frted alleles of the secondary mutation. Cre expression creates the cancer initiating mutation and removes the neo/stop cassette from lox-neo/stop-lox FlpO-ERT2, restricting its expression to initiated cancer cells. FlpO-ERT2 activity can then be induced at experimentally controlled times by tamoxifen administration, creating a secondary mutation by deleting frted gene alleles. This mouse model can be used to determine how 2 mutations occurring in a defined and controllable temporal order affect cancer phenotypes in vivo. We will use this mouse model to test whether the timing of Pten and Rb1 mutation alters prostate cancer phenotype. PTEN and RB1 mutation are common in human prostate cancer, with PTEN loss occurring early and RB1 loss occurring late. The late loss of RB1 is puzzling as its early loss is
known to initiate other human cancers. It is unknown whether PTEN and RB1 loss cooperate to drive prostate cancer progression or whether the temporal pattern of mutation influences prostate cancer phenotype. We postulate that the timing of Pten and Rb1 mutation will alter prostate cancer phenotypes in vivo because the effects of these mutations are dependent on genetic background. Two specific aims are proposed to create the lox-neo/stop-lox FlpO-ERT2 allele, to use it to alter the timing of Pten and Rb1 mutation in the mouse prostate cancer model, and to characterize the effects of these mutations on prostate cancer phenotypes in vivo.
描述(申请人提供):癌症进展是由基因突变、表型变异和选择的进化过程驱动的。因此,癌细胞的遗传背景是不断变化的。遗传背景将决定未来突变的性质,这些突变是可以容忍和选择的。特定新突变的影响将取决于它们发生的遗传背景。因此,突变的时间顺序预计会影响癌症的表型。然而,突变的时机如何影响癌症表型在很大程度上仍然是一个悬而未决的问题。回答这个具有挑衅性的问题(PQB5)意义重大,因为癌症预后和有效的个性化癌症治疗不仅取决于特定癌症中存在的突变的性质,还取决于它们获得的顺序。基因工程小鼠癌症模型在阐明癌症的遗传病因方面至关重要,但很少被用于解决PQB5。这是由于通常使用的基因工程方法固有的局限性;当产生多个突变时,突变的顺序要么未知,要么不可控制,要么不限于早期的癌细胞。目前进展的一个障碍是可以精确控制多个基因突变的时间和顺序的小鼠癌症模型的可用性。我们建议通过开发一种新的基于lox-neo/Stop-lox FlpO-ERT2转基因的小鼠癌症模型来克服这一障碍。该转基因编码一种FlpO重组酶,ERT2雌激素受体融合蛋白,其活性是他莫昔芬诱导的。转基因与组织特异性Cre转基因、致癌突变的等位基因和次级突变的等位基因相结合。Cre的表达产生了致癌突变,并从lox-neo/STOP-lox FlpO-ERT2中移除了neo/Stop盒,将其表达限制在启动的癌细胞中。然后,通过给药他莫昔芬,可以在实验控制的时间诱导FlpO-ERT2活性,通过删除Frt基因等位基因来产生二次突变。这个小鼠模型可以用来确定在体内以定义和可控的时间顺序发生的两个突变如何影响癌症表型。我们将使用这个小鼠模型来测试Pten和Rb1突变的时机是否会改变前列腺癌的表型。PTEN和RB1基因突变在人类前列腺癌中很常见,PTEN基因缺失发生较早,RB1基因缺失发生较晚。RB1的后期损失令人费解,因为它的早期损失是
已知会引发其他人类癌症。目前尚不清楚PTEN和RB1缺失是否共同推动前列腺癌的进展,或者突变的时间模式是否影响前列腺癌的表型。我们推测Pten和Rb1突变的时间会改变体内前列腺癌的表型,因为这些突变的影响取决于遗传背景。我们提出了创建lox-neo/Stop-lox FlpO-ERT2等位基因的两个特定目标,用它来改变小鼠前列腺癌模型中Pten和Rb1突变的时间,并在体内表征这些突变对前列腺癌表型的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID W. GOODRICH其他文献
DAVID W. GOODRICH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID W. GOODRICH', 18)}}的其他基金
YAP1 and RB1 cooperate to regulate lung cancer lineage plasticity and therapeutic resistance
YAP1和RB1合作调节肺癌谱系可塑性和治疗耐药性
- 批准号:
10829724 - 财政年份:2022
- 资助金额:
$ 22.16万 - 项目类别:
Coordinating and Data Management Center for Acquired Resistance to Therapy Network
获得性治疗耐药网络协调和数据管理中心
- 批准号:
10516537 - 财政年份:2022
- 资助金额:
$ 22.16万 - 项目类别:
Coordinating and Data Management Center for Acquired Resistance to Therapy Network
获得性治疗耐药网络协调和数据管理中心
- 批准号:
10682495 - 财政年份:2022
- 资助金额:
$ 22.16万 - 项目类别:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
NOTCH信号控制向雄激素非依赖性神经内分泌前列腺癌的转化
- 批准号:
10346091 - 财政年份:2019
- 资助金额:
$ 22.16万 - 项目类别:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
NOTCH信号控制向雄激素非依赖性神经内分泌前列腺癌的转化
- 批准号:
10524127 - 财政年份:2019
- 资助金额:
$ 22.16万 - 项目类别:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
NOTCH信号控制向雄激素非依赖性神经内分泌前列腺癌的转化
- 批准号:
10759015 - 财政年份:2019
- 资助金额:
$ 22.16万 - 项目类别:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
NOTCH信号控制向雄激素非依赖性神经内分泌前列腺癌的转化
- 批准号:
10641672 - 财政年份:2019
- 资助金额:
$ 22.16万 - 项目类别:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
NOTCH信号控制向雄激素非依赖性神经内分泌前列腺癌的转化
- 批准号:
10397535 - 财政年份:2019
- 资助金额:
$ 22.16万 - 项目类别:
(PQB5) Does the timing of Pten and Rb1 mutation affect prostate cancer phenotypes
(PQB5) Pten 和 Rb1 突变的时间是否影响前列腺癌表型
- 批准号:
8708795 - 财政年份:2013
- 资助金额:
$ 22.16万 - 项目类别:
The Role of Thoc1 in Normal Development and Cancer
Thoc1 在正常发育和癌症中的作用
- 批准号:
7332285 - 财政年份:2007
- 资助金额:
$ 22.16万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 22.16万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 22.16万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 22.16万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 22.16万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 22.16万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 22.16万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 22.16万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 22.16万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 22.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 22.16万 - 项目类别:
Studentship